Xunfei Healthcare Technology Co., Ltd. and Jiangxi Rimag Group Co., Ltd. based on their strengths and resources in their respective fields, have recently entered into a strategic cooperation agreement (the "Strategic Cooperation Agreement") after friendly negotiations. Pursuant to the Strategic Cooperation Agreement, the Company and Rimag are planning to commence cooperation in the following areas: (i) to carry out joint business and market development in the advantageous regions of both parties, and to jointly deepen the development of smart healthcare for grassroots level, close-knit medical consortiums and regional medical sharing centers; (ii) to achieve in-depth cooperation in respect of core products and business models of both parties, and to develop complementary businesses and realise synergies; (iii) to jointly design and explore innovative smart healthcare business investment models, and to explore applicable and replicable business models especially in the construction, operation, and management of a regional healthcare trusted data space as well as in industry monetisation; (iv) to conduct collaborative research and development, promotion and market application of medical vertical cognitive large models and medical imaging AI diagnostic large models; and (v) to jointly explore and develop smart healthcare management, chronic disease management, and post-hospital management of patients, etc., combining online smart healthcare management with offline physical examination, imaging, pathology, and electrocardiography. Rimag, a leading medical group specializing in medical imaging in China, is the operator and manager of a medical imaging platform that provides comprehensive medical imaging services and value to the entire medical imaging industry chain, with its main businesses including the provision of imaging center services, imaging solution services and Rimag Cloud services.

The Group is an AI-empowered healthcare solution provider, offering products and solutions that support a range of healthcare services, from health risk warnings, early screening, auxiliary diagnosis and treatment, as well as treatment effect evaluation to post-discharge management and chronic disease management. The directors of the Company are of the view that the Strategic Cooperation Agreement was entered into in the ordinary and usual course of business of the Group on terms that are fair and reasonable, on normal commercial terms or better terms and in the interests of the Company and its shareholders as a whole. This cooperation is not only an in-depth integration of technology and resources between the two parties, but also an innovative breakthrough in the deep synergy between medical AI enterprises and medical imaging service providers, achieving the industrial integration from technology complementation, scenario interconnection to ecological co-construction.

With the gradual deepening of the cooperation, the Company and Rimag is promoting the accelerated formation of a more efficient and fairer intelligent medical ecosystem with the dual logic of "technological revolution + ecological win-win", and injecting new kinetic energy into the strategy of Healthy China.